

Tm Bioscience To Manufacture Novel Breast Cancer Risk Testing Reagents For Intergenetics

Companies Sign Five Year Supply Agreement

TSX: TMC

TORONTO, July 15 - Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing market, today announced it has signed a five year agreement to supply custom Tag-It(TM) reagents to InterGenetics (Oklahoma City, Oklahoma) for OncoVue(TM). According to InterGenetics, Oncovue(TM) has been developed as the first genetic-based Breast Cancer Risk Test relevant to all women. The agreement anticipates InterGenetics will purchase a minimum of \$7.5 million in reagents from Tm over the five year period. The agreement is contingent on Tm delivering Tag-It(TM) reagents which perform according to InterGenetics' specifications.

"InterGenetics has identified and validated a large number of genetic biomarkers linked to breast cancer, and our goal was to develop a clinical test that will help women understand their personal, age-related risk of developing this disease," said Dr. Craig Shimasaki, President and CEO of InterGenetics. "With a potential market of over 30 million tests, growing at 2 million tests per year in the U.S. alone, we needed to select a production technology which was scalable for very high throughput. Our OncoVue(TM) breast cancer risk test was actually designed and developed using the Tag-It(TM) universal array platform. With state-of-the-art cGMP manufacturing facilities that can handle anticipated demand, Tm Bioscience proved to be the ideal commercialization partner for our first product."

"We plan to begin supplying products to InterGenetics in the second half of 2005. As InterGenetics completes clinical validation of additional genetic markers for ovarian and other cancers, we anticipate expanding our agreement to include these new cancer risk assessment products," said Greg Hines, President and CEO of Tm Bioscience. "Our relationship with InterGenetics reflects Tm's value as a commercialization partner to both public and private institutions seeking to bring their innovative genetic discoveries from the laboratory to the market."

Breast cancer is one of the most frequently diagnosed cancers among females. The American Cancer Society estimates approximately 211,000 women in the United States will be diagnosed with invasive breast cancer this year. Screening by mammography is recommended annually for women over 40 with an estimated 30 million mammograms performed each year on women between the ages of 40 and 64.

About Oncovue™

The OncoVue™ breast cancer risk test from InterGenetics will be a simple mouthwash test that analyzes DNA from a woman's cheek cells and examines combinations of genes which, in conjunction with personal history and

environmental factors, help determine a woman's risk for developing breast cancer. OncoVue(TM) was developed based on an ongoing study of more than 13,000 women. OncoVue(TM) will examine a subset of more than 85 common genetic variations included in this study. The information is useful because women at high risk for breast cancer can opt for preventative medication or be directed to more comprehensive screening for early detection, where long term survival is the greatest.

About InterGenetics

InterGenetics, a genetics-based cancer-risk testing and cancer treatment company is emerging as an innovator in the frontier of genetic medicine. The company's lead product, the OncoVue(TM) Breast Cancer Risk Test, uses proprietary gene combinations and DNA assessment technology developed by InterGenetics' scientists to quickly and accurately identify women who are at high risk of developing breast cancer, potentially many years in advance of their diagnosis. InterGenetics has a promising research pipeline of predictive tests for other cancers such as ovarian, colon, prostate, and pancreatic cancer. The company's core research has future application in also predicting risk for heart disease, diabetes and in enhancing the effectiveness of drug therapies and preventative medicine in these fields. www.intergenetics.com

About Tag-It(TM) reagents and genetic tests

Tm Bioscience's product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has commercialized Analyte Specific Reagents(*) and a series of Tag-It(TM) tests(xx) for a variety of genetic disorders. The Company's Tag-It(TM) Cystic Fibrosis (CF) Kit is the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration (FDA) as an in vitro device (IVD) for diagnostic use in the United States. All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion. Assays from Tm operate on the Luminex xMAP(R) system, a well-established bead based instrument. Combined, the Universal Array and Luminex instrument enable the rapid production of flexible, high-throughput, low-cost DNA-based tests.

(*) Analyte Specific Reagent. Analytical and performance characteristics are not established.

(xx)For Investigational Use Only. The performance characteristics of these products have not been established.

About Tm Bioscience - Putting the Human Genome to Work™

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic disorders, drug metabolism, and infectious diseases. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found

at www.tmbioscience.com.

For further information: INVESTOR RELATIONS CONTACTS: Tm Bioscience - Canada: James Smith, The Equicom Group, Tel.: (416) 815-0700, Email: jsmith@equicomgroup.com; Tm Bioscience - U.S.: Sharon Weinstein, Euro RSCG Life NRP, Tel.: (212) 845-4271, Email: sharon.weinstein@eurorscg.com; InterGenetics: Jane Braden, Tel.: (405) 715-3232;

To request a free copy of this organization's annual report, please go to <http://www.newswire.ca> and click on reports@cnw.

To update your contact information or to be removed from this dissemination list, please e-mail pressreleases@equicomgroup.com.